Jo: True investors in this company have heard the same old PR for a long, long time. Repeating it will not further sit well with investors and management has likely woken up to that fact. At this point, they obviously have nothing new to announce. Absent significant sales (which I do not see on the horizon), the only things, in my mind, that will make this stock move in the positive direction will be: (1) some form of business arrangement with a large entity with industry experience, such as Stryker, GE, Baxter, a major pharma, etc.; and/or (2) FDA approvals. I personally hope that they are working on (1), as they do not have the capital to do anything with (2).
